Abstract: The present invention provides novel compounds and methods for hydrocyanines derived from near-infrared cyanine dyes, as reactive oxygen species probes in imaging. In certain embodiments, the present invention provides reduced dyes as substrates for ELISA and Western blots.

Abstract: Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

Abstract: Compositions and methods for increasing fluorescent signals generated by biomarkers are described. This serves to increase the accuracy of results when the biomarkers are used for the detection and diagnosis of physiological conditions, such as organ function and plasma volume.

Abstract: Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.

Abstract: Methods to use medical imaging to monitor the molecule penetration into CNS during ultrasound-mediated delivery are disclosed. The method states a two-step process to predict the amount of molecular penetration which is based on the observation of medical imaging. The first is to propose a unified exposure input to unify the exposure condition so as to build a transferred relation to imaging index. The second is to propose a unified imaging index to unify the imaging readout so as to build a reliable transferred relation to molecular concentration. Linking these two, the molecular penetration induced by ultrasound irradiation can be estimated from medical imaging with ultrasound exposure conditions and molecular sizes.

Abstract: Exemplary probes for detecting hypoxic cells and tissue have the structure of

Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

Abstract: This invention is directed to non-benzenoid aromatic compounds. Other aspects include methods of using non-benzenoid aromatic compounds for imaging and phototherapeutic uses thereof. Non-benzenoid compounds provided herein generally have one or more substituent groups which allow tailoring of the spectral properties or provide photoreactivity or targeting ability.

Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

Abstract: Disclosed herein, the invention pertains to methods and compositions that find use in treatment, diagnosis, prognosis and characterization of disease and disease samples based on the ability of a disease sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is a pre-targeting moiety; M is a macromolecular carrier, C is a detectable moiety; and T is a compound for delivery to a target, including for example a therapeutic compound.

Abstract: The present invention is a device for high-throughput detection, screening and disease management of cervical disease. The device is comprised of a solid support featuring multiple well-separated areas, each accommodating a patient sample, leading to simultaneous evaluation of patient samples. The device enables cytological staining, cervical Pap staining, and immunochemical staining using antibodies or combination of antibodies which are capable of binding to biomarkers that are overexpressed in cancer including in cervical carcinoma and dysplasia, as compared to normal controls. The device can be used in either manual or automated mode, and applied to any biological fluid or cell suspension from any biological specimen in view of a variety of cell biology assays, and in view of detection and screening of cervical and other diseases.

Abstract: The disclosure is related to a chemical structure, a preparation and an imaging method of a tumor imaging tracer, especially to a SPECT radionuclide-labeled trimeric cyclic RGD peptide: 99mTc-4P-RGD3which functions as a ligand to be combined with integrin ?v?3 receptor in tumor for tumor imaging. The preparation includes linking HYNIC-OSu with 4P-RGD3 to form HYNIC-4P-RGD3 and then chelating HYNIC with 99mTc to create 99mTc-4P-RGD3Animal biodistribution and imaging experiments reveal higher uptake in tumor and lower uptake in normal organs, therefore the disclosure can improve image quality, Through animal metabolic experiments, the original form of 99mTc-4P-RGD3 can be still excreted without the evidence of further metabolites in urine and feces. According to the disclosure, the tumor imaging tracer 99mTc-4P-RGD; combined with the integrin ?v?3 solves the issue of high background uptake in normal organs, such that radio-labeled SPECT imaging tracers are more suitable for animal whole-body tumor evaluation.

Abstract: The present invention is directed to methods of determining the presence or absence of a bacterial infection in a patient using isotopically-labeled tyrosine and/or isotopically-labeled p-hydroxyphenylacetic acid.

Abstract: Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.

Abstract: The present invention relates to improved radiotracer imaging agent compositions, which comprises 18F-labelled biological targeting moieties, wherein impurities which affect imaging in vivo are identified and suppressed. Also provided are radiopharmaceuticals comprising said improved compositions, together with radiofluorinated aldehyde compositions useful in preparing said radiotracer compositions. The invention also includes methods of imaging and/or diagnosis using the radiopharmaceutical compositions described.

Abstract: The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.

Abstract: The present invention relates to methods useful in the selection of cancer patients suitable for treatment with therapies directed at c-Met. The method employs imaging agents which comprise 18F-radiolabelled c-Met binding peptides suitable for positron emission tomography (PET) imaging in vivo. Also disclosed are methods of treatment, methods of monitoring therapy directed atc-Met and the use of the imaging agents and peptides in the methods of the invention.

Abstract: Methods and apparatus are described herein for fluorescent imaging of a retina using a head-mountable device. The retina is illuminated by a head-mountable device (HMD) with light at an excitation wavelength of a fluorophore in the retina and imaged by the HMD at an emission wavelength of the fluorophore. The direction of gaze of a user of the HMD could be determined from the retinal image. The pattern of vasculature in the retinal image could be used to identify the user of the HMD. Information in the retinal image could be used to determine the medical state of the user and diagnose disease states. Fluorescent agents can be introduced into the vasculature of the wearer of the HMD to facilitate these or other applications of fluorescent imaging of the retina using the HMD.

Abstract: A radio- or chemo-sensitizing compound is described herein. The compound comprises a nanoparticle and attached to the nanoparticle; (i) a DNA repair inhibitor; and (ii) a nuclear localization signal element (NLS); each optionally attached via one or more linker moieties.

Abstract: The present invention relates to a nanoparticle having a linker connected to a long alkane or alkene chain, and a method for preparing the nanoparticle. The alkyl chain of C10-30 introduced with a ligand of the present invention can be coated on a hydrophobic nanoparticle through a noncovalent bond, enabling easy introduction of various ligands to the nanoparticle, and the nanoparticle having various functional groups prepared using the method can be applied to fluorescent detection, MRI, raman spectroscopy, optical detection, PET, SPECT, or gamma image device, and the ligand of the visualization agents can be modified to be used for new vessels detection, cancer cell detection, immunocyte detection, hepatocyte detection, cell death detection, and gene detection.

Abstract: Provided are therapeutic and diagnostic somatostatin analogs including radiotherapeutic and radiodiagnostic reagents, and methods of making and use thereof.

Abstract: Disclosed viscosity-sensitive reporter compounds and methods allow tracing the changes in viscosity in a biological sample/environment (e.g., in medical, biochemical, biological, and/or pharmaceutical applications). Compounds and methods of the present disclosure can be used to identify the localization and the rheological state of hydrogels, their degradation products and other biostructural materials, including surgical implants, as well as the effectiveness of drug delivery by hydrogel carriers.

Abstract: This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.

Abstract: The present invention relates to a method for preparing a pharmaceutical formulation of lanthanide chelate in powder form, wherein the powder constitutes a mol/mol excess of free chelate of between 0.002 and 0.4%.

Abstract: Compositions and methods for evaluating a pharmacokinetic property of an ophthalmic agent administered by intravitreal injection are provided.

Abstract: An ophthalmic radiation device using a polymeric radiation-source implemented as either a polymer molecularly bonded with a radioisotope or a polymeric encasement of a radioisotope.

Abstract: The invention provides a conjugate with fluorochrome moiety F coupled to a targeting moiety T. Moiety F is described by formula (I), and the targeting moiety T is characterized in that it has affinity to a tumor marker, such as an antibody or antibody fragment. The conjugate may be used for tumor diagnostics including photodetection of tumor nodules during resection surgery.

Abstract: Non-invasive method of monitoring by radioactivity bioscanning the distribution of a biological entity in a subject in vivo by administering to the subject a radioiodinated form of the biological entity. The radioiodinated form is prepared by contacting an aqueous suspension of the biological entity with a radioiodinated construct of the structure F-S-L where F comprises a radioiodinated tyrosine moiety, S is a spacer covalently linking F to L, and L is a lipid.

Abstract: This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.

Abstract: Lipid-based nanoparticle compositions are provided. The compositions generally comprise lipid-hydrophilic polymer-amyloid binding ligand conjugates, and may be liposomal compositions. The compositions, including the liposomal compositions, may be useful for imaging and/or the treatment of amyloid-? plaque deposits characteristic of Alzheimer's Disease.

Abstract: Provided herein are compositions and methods of preparing nanoparticle aggregates.

Abstract: The present disclosure provides activatable and detectable membrane-interacting peptides that, following activation, can interact with phospholipid bilayers, such as cell membranes. The present disclosure also provides methods of use of such compounds. The compounds of the present disclosure are of the general structure X1a-A-X2-Z-X1b, where A is a membrane-interacting peptide region having a plurality of nonpolar hydrophobic amino acid residues that, following separation from portions Z, is capable of interaction with a phospholipid bilayer; Z is an inhibitory peptide region that can inhibit the activity of portion A; X2 is a cleavable linker that can be cleaved to release cleavage products from the compound; and X1a and X1b are optionally-present chemical handles that facilitate conjugation of various cargo moieties to the compound. Prior to cleavage of the composition at X2, the composition acts as a promolecule that does not associate with cellular membranes to a significant or detectable level.

Abstract: The invention relates to a processing apparatus for processing cardiac data of a living being and to an imaging system comprising the processing apparatus. A distribution of Fractional flow reserve (FFR) values being indicative of the FFR of different coronary arteries of the living being, a distribution of myocardial perfusion values like values of an iodine map being indicative of the myocardial perfusion of different portions of the myocardium of the living being and assignments between coronary arteries and portions of the myocardium of the living being are used for determining degrees of correspondence between FFR values and myocardial perfusion values. This allows for, for example, a determination of the reliability of the FFR values, if the myocardial perfusion values are known to be reliable, based on the determined degrees of correspondence.

Abstract: This invention provides compounds and compositions useful as imaging tracers for positron emission tomography myocardial perfusion imaging (PET MPI). Compounds in accordance with embodiments of the invention will generally comprise three structural elements: i) a triphenylphosphonium moiety; ii) a chelating element; and iii) a hydrophobic element. The tracer compounds are preferably radiolabeled with 64Cu or 18F. Also provided are methods for synthesizing the compounds, methods for derivatizing the compounds, and derivatives thereof.

Abstract: Photosensitive molecular switch, having a chelate ligand, a metal ion bonded coordinatively to the chelate ligand, the metal ion being selected from the group of metal ions consisting of Mn2+, Mn3+, Fe2+, Fe3+, Co2+ and Ni2+, a photochromic system which is bonded covalently to the chelate ligand and can be isomerized by irradiation, this system being bonded coordinatively to the metal ion in one configuration and not bonded to the metal ion in the other configuration.

Abstract: Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or tissue retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) cargo moieties (portion DA and DB).

Abstract: A microfluidic chip for steam distillation includes a chip body and a condenser. The chip body includes a steam inlet and a steam outlet. The steam inlet is connected to the steam outlet by a micro channel. The micro channel includes a first channel, a second channel, and a receiving space having an enlarged cross sectional area larger than a cross sectional area of each of the first and second channels. The first channel connects the steam inlet with the receiving space. The second channel windingly connects the steam outlet with the receiving space. The condenser includes a condensing channel inlet and a condensing channel outlet. The condenser further includes a condensing channel windingly connecting the condensing channel inlet with the condensing channel outlet. The steam outlet 11b intercommunicates with the condensing channel inlet.

Abstract: Preferred embodiments relate to compositions of inherently radiopaque, biocompatible, bioresorbable polymeric particles and methods of using them for embolizing a body lumen.

Abstract: Disclosed is a targeted molecular imaging probe consisting of a signal component, a component with a targeted affinity to Cx43 and a linker. The biochemical variation characteristic of connexin43 (Cx43) associated with cardiovascular diseases (especially arrhythmia) and neoplastic diseases can be reflected in the form of an image by using the targeted molecular imaging probe capable of being detected by an imaging device, to achieve in vivo molecular imaging.

Abstract: A computerized system and method for determining an optimum amount of radiopharmaceutical therapy (RPT) to administer, comprising: performing processing associated with obtaining activity image information related to at least one agent for sub-units of at least one imaged organ from at least one detector; performing processing associated with running at least one calculation for the activity image information, using at least one computer application, to obtain absorbed dose rate image information; and performing processing associated with adding the absorbed dose rate image information, using, the at least one computer application, to obtain RPT total absorbed dose image information for the at least one imaged organ; wherein macroscopic distribution measurements that are related to microscopic or sub-unit distribution of the at least one agent are utilized.

Abstract: Measurements of the squalene content in oil-in-water emulsions can be used as a way of checking for problems during production. In particular, it has been found that a drop in squalene content can indicate that filtration problems occurred. Testing the squalene content in the final lots is easier than investigating the characteristics of the filter, and so a squalene assay simplifies the quality control of oil-in-water emulsions.

Abstract: The present invention relates to a CT contrast agent for detecting a thrombus, comprising fibrin-targeted peptide sequence-conjugated glycol chitosan-gold nanoparticles. The CT contrast agent for detecting a thrombus according to an embodiment of the present invention may allow rapid and repeated acquisition of CT image information related to the size and location of a thrombus in cardio-cerebral vascular thrombosis, and also enables the imaging monitoring of cerebral thrombus.

Abstract: The invention relates to a kit for preparation of target radiopharmaceuticals, a method of using the kit to prepare target radiopharmaceuticals and use of the target radiopharmaceuticals. The target radiopharmaceuticals comprise a radio-nuclear loading on liposome and inhibit the tumor growth and metastatic progression of head and neck cancer, lung cancer and brain cancer. The radiopharmaceuticals may be used for treating the mentioned cancers.

Abstract: A system and method for measuring a radioactive concentration of a radiopharmaceutical is disclosed. The system includes a container, an interrogation region associated with the container, a radiation detector, a signal capture device, and a microprocessor system. The radiation detector focuses radiation emitted from the interrogation region, a measurement of which is then obtained by the signal capture device. The microprocessor system is in data communication with the signal capture device, and is capable of calculating the radioactive concentration of the radiopharmaceutical contained in the interrogation region from the radiation measurement obtained by the signal capture device.

Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.

Abstract: Compounds and a method for imaging myocardial perfusion, including administering to a patient a compound linked to an imaging moiety, wherein the compound binds MC-1, and scanning the patient using diagnostic imaging. Kits including the compound or precursor compounds linked or not linked to an imaging moiety are also described.

Abstract: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.

Abstract: The present invention relates to contrast medium composition and a method of bio imagination using the same. The contrast medium composition of the present invention includes a biomolecule, DNA nanostructure, as an active ingredient, is fundamentally non-cytotoxic and non-immunogenic and is not likely to induce safety problems that may be observed in other organic or inorganic contrast medium composition. In addition, the contrast medium composition of the present invention not only facilitates diagnosis of disease through sufficient contrast enhancement effect by showing excellent cellular uptake and intracellular stability and can visualize even SLNs which is difficult to be visualized traditionally, so can judge metastasis of cancer easily and apply lower invasive treatment.

Abstract: This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.